{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:54:23Z","timestamp":1792637663099,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jccjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jcrc.2016.06.023","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T09:18:52Z","timestamp":1467710332000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4680-1116","authenticated-orcid":false,"given":"Keaton S.","family":"Smetana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L. Thompson","family":"Bastin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Oyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00003246-199301000-00019","article-title":"Neurologic complications of critical medical illnesses","volume":"21","author":"Bleck","year":"1993","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.jcrc.2016.06.023_bb0010","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/01.WNL.0000125184.88797.62","article-title":"Detection of electrographic seizures with continuous EEG monitoring in critically ill patients","volume":"62","author":"Claassen","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jcrc.2016.06.023_bb0015","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1007\/s00415-012-6509-3","article-title":"Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults","volume":"259","author":"Hamer","year":"2012","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jcrc.2016.06.023_bb0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: a multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.jcrc.2016.06.023_bb0025","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1056\/NEJMct1206045","article-title":"Continuous renal-replacement therapy for acute kidney injury","volume":"367","author":"Tolwani","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/ajkd.2001.22068","article-title":"Renal replacement therapy in the patient with acute brain injury","volume":"37","author":"Davenport","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcrc.2013.05.018","article-title":"Practical considerations for the dosing and adjustment of continuous renal replacement therapy in the intensive care unit","volume":"28","author":"Galvagno","year":"2013","journal-title":"J Crit Care"},{"issue":"17","key":"10.1016\/j.jcrc.2016.06.023_bb0040","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa0902413","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcrc.2016.06.023_bb0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/gfg055","article-title":"Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters","volume":"18","author":"Troyanov","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.jcrc.2016.06.023_bb0050","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"37","author":"Choi","year":"2009","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/bja\/85.4.599","article-title":"The role of albumin in critical illness","volume":"85","author":"Nicholson","year":"2000","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1525-139X.2008.00552.x","article-title":"Continuous renal replacement therapy in sepsis and multisystem organ failure","volume":"22","author":"Joannidis","year":"2009","journal-title":"Semin Dial"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0065","series-title":"Dilantin (R) (phenytoin) [package insert]","year":"2011"},{"issue":"16","key":"10.1016\/j.jcrc.2016.06.023_bb0070","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1001\/jama.1977.03280170044025","article-title":"Removal of phenytoin by hemodialysis in uremic patients","volume":"238","author":"Martin","year":"1977","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CNP74059","article-title":"Successful hemodialysis in a phenytoin overdose: case report and review of the literature","volume":"74","author":"Ghannoum","year":"2010","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007691-199402000-00009","article-title":"Effect of continuous hemofiltration on phenytoin elimination","volume":"16","author":"Lau","year":"1994","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.1016\/j.jcrc.2016.06.023_bb0085","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/1060028013503131","article-title":"Phenytoin removal by continuous venovenous hemofiltration","volume":"47","author":"Oltrogge","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.jcrc.2016.06.023_bb0090","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1592\/phco.28.11.1391","article-title":"Therapeutic drug monitoring of phenytoin in critically ill patients","volume":"28","author":"von Winckelmann","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0095","series-title":"Thompson Micromedex Micromedex healthcare series: DRUGDEX system - 2015","year":"2008"},{"issue":"8\u20139","key":"10.1016\/j.jcrc.2016.06.023_bb0100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-003-0655-6","article-title":"Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers","volume":"59","author":"Strolin Benedetti","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0105","series-title":"Keppra (R) (levetiracetam) [package insert]","year":"2009"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/phar.1615","article-title":"Levetiracetam pharmacokinetics in a patient receiving continuous venovenous hemofiltration and Venoarterial extracorporeal membrane oxygenation","author":"Nei","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s12028-016-0242-1","article-title":"Levetiracetam pharmacokinetics during continuous venovenous hemofiltration and acute liver dysfunction","author":"New","year":"2016","journal-title":"Neurocritical Care"},{"issue":"11","key":"10.1016\/j.jcrc.2016.06.023_bb0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0125","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1053\/j.ajkd.2006.04.081","article-title":"Use of continuous venovenous hemodiafiltration in a case of severe phenobarbital poisoning","volume":"48","author":"Lal","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/1556350500395040","article-title":"Successful treatment of acute phenobarbital intoxication by hemodiafiltration","volume":"44","author":"van de Plas","year":"2006","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0135","series-title":"Phenobarbital [package insert]","year":"2007"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0140","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt1977216736","article-title":"Pharmacokinetics and bioavailability of sodium valproate","volume":"21","author":"Klotz","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0145","series-title":"Stavzor (R) (valproic acid) [package insert]","year":"2009"},{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1525-139X.2005.18106.x","article-title":"Extracorporeal management of valproic acid toxicity: a case report and review of the literature","volume":"18","author":"Al Aly","year":"2005","journal-title":"Semin Dial"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00007691-199906000-00005","article-title":"Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion","volume":"21","author":"Franssen","year":"1999","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0160","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0272-6386(99)70235-0","article-title":"Successful treatment of valproic acid overdose with hemodialysis","volume":"33","author":"Johnson","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1528-1157.1979.tb04808.x","article-title":"Sodium valproate, serum level and clinical effect in epilepsy: a controlled study","volume":"20","author":"Gram","year":"1979","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000135677","article-title":"Hemodiafiltration and high-flux hemodialysis significantly reduce serum valproate levels inducing epileptic seizures: case report","volume":"26","author":"Gubensek","year":"2008","journal-title":"Blood Purif"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0175","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1345\/aph.1P308","article-title":"High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy","volume":"45","author":"de Maat","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0180","series-title":"Tegretol (R) (carbamazepine) [package insert]","year":"2014"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0185","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007691-198609000-00011","article-title":"Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose","volume":"8","author":"Vree","year":"1986","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.jcrc.2016.06.023_bb0190","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/15563650.2014.973572","article-title":"Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"52","author":"Ghannoum","year":"2014","journal-title":"Clin Toxicol"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1542-4758.2011.00563.x","article-title":"Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose","volume":"15","author":"Harder","year":"2011","journal-title":"Hemodial Int"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10047-014-0754-4","article-title":"Successful treatment of severe carbamazepine toxicity with 5% albumin-enhanced continuous venovenous hemodialysis","volume":"17","author":"Narayan","year":"2014","journal-title":"J Artif Organs"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000335608","article-title":"Is conventional hemodialysis enough to manage carbamazepine intoxication?","volume":"33","author":"Azak","year":"2012","journal-title":"Blood Purif"},{"issue":"5","key":"10.1016\/j.jcrc.2016.06.023_bb0210","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00134-012-2501-8","article-title":"Increased unbound drug fraction in acute carbamazepine intoxication: suitability and effectiveness of high-flux haemodialysis","volume":"38","author":"Sikma","year":"2012","journal-title":"Intensive Care Med"},{"issue":"8948","key":"10.1016\/j.jcrc.2016.06.023_bb0215","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","article-title":"Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK lamotrigine\/carbamazepine monotherapy trial group","volume":"345","author":"Brodie","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0220","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.109.030593","article-title":"Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine","volume":"39","author":"Flesch","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.ftd.0000196660.89984.8d","article-title":"Acute oxcarbazepine, benazepril, and hydrochlorothiazide overdose with alcohol","volume":"28","author":"Furlanut","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0230","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1600-0404.1993.tb04106.x","article-title":"Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment","volume":"87","author":"Friis","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0235","series-title":"Aptiom (eslicarbazepine) package insert","year":"2013"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy","volume":"69","author":"Striano","year":"2006","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","article-title":"Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate","volume":"46","author":"Maia","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0250","series-title":"Zarontin (R) (ethosuximide) [package insert]","year":"2009"},{"issue":"11","key":"10.1016\/j.jcrc.2016.06.023_bb0255","first-page":"1757","article-title":"Hemodialysis clearance of ethosuximide in patients with chronic renal disease","volume":"38","author":"Marbury","year":"1981","journal-title":"Am J Hosp Pharm"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0260","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1469-8749.1982.tb13703.x","article-title":"Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal)","volume":"24","author":"Callaghan","year":"1982","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0265","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archneur.1973.00490210058007","article-title":"IMproved control of epilepsy by monitoring plasma ethosuximide","volume":"28","author":"Sherwin","year":"1973","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0270","series-title":"Potiga (R) (ezogabine) [package insert]","year":"2012"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/157488470904141105142635","article-title":"Effect of hemodialysis on pharmacokinetics of ezogabine\/retigabine and its N-acetyl metabolite in patients with end stage renal disease","volume":"9","author":"Tompson","year":"2014","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0280","series-title":"Potiga (ezogabine) package insert","year":"2012"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0285","series-title":"Felbatol (R) (felbamate) [package insert]","year":"2011"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(97)01021-8","article-title":"Felbamate and meprobamate: a comparison of their anticonvulsant properties","volume":"27","author":"Frey","year":"1997","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0295","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/hdi.12047","article-title":"Pharmacokinetics of meprobamate in overdose treated with continuous venovenous hemodiafiltration (CVVHDF)","volume":"17","author":"Ceschi","year":"2013","journal-title":"Hemodial Int"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0300","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.43.4.688","article-title":"Felbamate monotherapy for partial-onset seizures: an active-control trial","volume":"43","author":"Faught","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0305","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.410320313","article-title":"Felbamate monotherapy: controlled trial in patients with partial onset seizures","volume":"32","author":"Sachdeo","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0310","series-title":"Neurontin (R) (gabapentin) [package insert]","year":"2015"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0315","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/j.1552-4604.1995.tb05020.x","article-title":"Disposition of gabapentin in anuric subjects on hemodialysis","volume":"35","author":"Wong","year":"1995","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0320","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007691-200308000-00007","article-title":"Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study","volume":"25","author":"Lindberger","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0325","series-title":"Lyrica (R) (pregabalin) [package insert]","year":"2013"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0330","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0091270003251119","article-title":"Pharmacokinetics of pregabalin in subjects with various degrees of renal function","volume":"43","author":"Randinitis","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0335","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.ftd.0000158874.54100.1a","article-title":"MC: analysis of pregabalin at therapeutic concentrations in human plasma\/serum by reversed-phased HPLC","volume":"27","author":"Berry","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0340","series-title":"Vimpat (R) (lacosamide) [package insert]","year":"2014"},{"issue":"10","key":"10.1016\/j.jcrc.2016.06.023_bb0345","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40262-013-0080-7","article-title":"Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide","volume":"52","author":"Cawello","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0350","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061908","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0355","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S5189","article-title":"Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety","volume":"5","author":"Kellinghaus","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0360","series-title":"Lamictal (R) (lamotrigine) [package insert]","year":"2010"},{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0365","first-page":"25","article-title":"Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis","volume":"19","author":"Fillastre","year":"1993","journal-title":"Drugs Exp Clin Res"},{"issue":"1","key":"10.1016\/j.jcrc.2016.06.023_bb0370","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000338966","article-title":"Successful treatment of severe lamotrigine and clonazepam poisoning by blood purification","volume":"34","author":"Lu","year":"2012","journal-title":"Blood Purif"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0375","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-5618.2010.00818.x","article-title":"Lamotrigine and hemodialysis in bipolar disorder: case analysis of dosing strategy with literature review","volume":"12","author":"Kaufman","year":"2010","journal-title":"Bipolar Disord"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0380","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0385","series-title":"Mysoline (R) (primidone) [package insert]","year":"2009"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0390","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00007691-199005000-00012","article-title":"Clearance of phenylethylmalonamide during haemodialysis of a patient with renal failure","volume":"12","author":"Streete","year":"1990","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00313107","article-title":"Primidone metabolism in renal insufficiency and acute intoxication","volume":"221","author":"Heipertz","year":"1979","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jcrc.2016.06.023_bb0400","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/j.1552-4604.1982.tb02679.x","article-title":"Pharmacokinetics of primidone elimination by uremic patients","volume":"22","author":"Lee","year":"1982","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0405","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1528-1157.1970.tb03905.x","article-title":"A clinical study of serum primidone levels","volume":"11","author":"Booker","year":"1970","journal-title":"Epilepsia"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0410","series-title":"Topamax (R) (topiramate) [package insert]","year":"2009"},{"issue":"5","key":"10.1016\/j.jcrc.2016.06.023_bb0415","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","article-title":"Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment","volume":"108","author":"Manitpisitkul","year":"2014","journal-title":"Epilepsy Res"},{"issue":"1\u20132","key":"10.1016\/j.jcrc.2016.06.023_bb0420","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jns.2009.10.001","article-title":"Possible removal of topiramate by continuous renal replacement therapy","volume":"288","author":"Browning","year":"2010","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.jcrc.2016.06.023_bb0425","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0430","series-title":"Vigabatrin (Sabril) [package insert]","year":"2015"},{"issue":"3","key":"10.1016\/j.jcrc.2016.06.023_bb0435","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1059-1311(96)80043-4","article-title":"Vigabatrin dosing during haemodialysis","volume":"5","author":"Bachmann","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.jcrc.2016.06.023_bb0440","series-title":"Zonegran (R) (zonisamide) [package insert]","year":"2015"},{"issue":"8","key":"10.1016\/j.jcrc.2016.06.023_bb0445","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.0013-9580.2004.30603.x","article-title":"Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis","volume":"45","author":"Ijiri","year":"2004","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0450","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199812000-00001","article-title":"Clinical pharmacology and therapeutic drug monitoring of zonisamide","volume":"20","author":"Mimaki","year":"1998","journal-title":"Ther Drug Monit"},{"issue":"12","key":"10.1016\/j.jcrc.2016.06.023_bb0455","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2146\/ajhp080250","article-title":"Stability of zonisamide in extemporaneously compounded oral suspensions","volume":"66","author":"Abobo","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"10.1016\/j.jcrc.2016.06.023_bb0460","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/00912700122010933","article-title":"Midazolam disposition in patients undergoing continuous venovenous hemodialysis","volume":"41","author":"Bolon","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jcrc.2016.06.023_bb0465","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s001340100965","article-title":"Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome","volume":"27","author":"Tsubo","year":"2001","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2016.06.023_bb0470","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08860229609052800","article-title":"Hemodiafiltration in pentobarbital poisoning","volume":"18","author":"Bironneau","year":"1996","journal-title":"Ren Fail"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0475","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00007691-198512000-00023","article-title":"Hemodialysis clearance of pentobarbital during continuous infusion","volume":"7","author":"Wermeling","year":"1985","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.jcrc.2016.06.023_bb0480","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF01705413","article-title":"The use of propofol for sedation of critically ill patients undergoing haemodiafiltration","volume":"21","author":"Eddleston","year":"1995","journal-title":"Intensive Care Med"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088394411630154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088394411630154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:27:55Z","timestamp":1718681275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088394411630154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":96,"alternative-id":["S088394411630154X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2016.06.023","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2016.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}